You searched for "video"
Patient portals
In May 2012, the Department of Health published its information strategy ‘Power of information’ which aims to put us all in control of the health and care information we need [1]. As a part of its information strategy a key...SMILE: sustaining medical education in a lockdown environment
2020 posed challenges to medical education like never seen before. In an effort to contain and slow the spread of coronavirus all UK medical schools ceased or reduced face-to-face contact. This sudden, and for many, unexpected change resulted in pressures...Remote working: what can health professionals learn from business?
Remote working has been widely used in business for many years but before COVID-19, this was not the case within healthcare settings. This article seeks to review the advantages, challenges and solutions which users of remote working in business have...Prostate abscess
Prostate abscess (PA) is a relatively uncommon clinical condition which is often difficult to diagnose because clinical symptoms are non-specific. It may be associated with a significant fatality rate, estimated to be between 3% and 30%, which may reflect its...Pelvic floor imaging – a brief synopsis
Background Pelvic floor imaging is an important part of both gastrointestinal and functional urology / urogynaecological departments. Symptoms such as obstructive defecation, incontinence and sphincter complex disorders have a significant impact on patient lifestyle and physical / mental well-being [1,2]....
Dual therapy for OAB in children
Overactive bladder (OAB) is a disorder frequently encountered by the paediatric urologist. Morin et al. report the results of the first known study on the efficacy of mirabegron (a β3 adrenoceptor agonist) as add-on therapy in paediatric patients with refractory...
Solifenacin and mirabegron are safe and effective in combination
Antimuscarinic agents remain the mainstay of medical management of bladder overactivity. Limited somewhat by their tolerability, the new agent mirabegron, a β3-adrenoreceptor agonist, has been approved as an alternative. There is little known however about the possible synergistic effects of...
